Mechanical Growth Factor Promotes FOXP3 Expression in Regulatory T Cells and Enhances its Function in Treating Ankylosing Spondylitis
Abstract BackgroundTo verify that mechanical growth factor (MGF) may be an effective target for treating ankylosing spondylitis. MethodsFOXP3 expression was measured in Treg cells from healthy male subjects treated with MGF. A rat model of ankylosing spondylitis was established, and the levels of ankylosing spondylitis-related factors (tumor necrosis factor [TNF]-α, interleukin [IL]-2, and IL-10) were measured. ResultsWe found that the proliferation and total number of Treg cells, as well as FOXP3 expression levels, increased significantly in the MGF-treated groups versus in the control. The levels of inflammation, bone destruction, and new bone formation were significantly decreased in animals treated with MGF compared to in the control group. TNF-α expression decreased significantly, while IL-2 and IL-10 levels increased significantly in the MGF group compared to in the control. ConclusionsMGF may delay disease progression in ankylosing rats by inducing FOXP3 expression, promote FOXP3+ Treg cell proliferation and differentiation and reducing the expression of TNF-α and increasing the expression of IL-10 and IL-2.